Payment Commission Data Act of 2019

H.Res. 152 - Calling for a formal end of the Korean war, all provisions. H.Res. 495 - Expressing the Sense of the House of Representatives regarding the Prevention of Iran from Obtaining or Developing Nuclear Weapons H.Con.Res.123 - Yemen War Powers Resolution H.R. 1264 - To sunset the 2001 Authorization for Use of Military Force H.R. 2407 - Promoting Human Rights for Palestinian Children Living Under Israeli Military Occupation Act H.R. 2456 - To repeal the 2002 Authorization for Use of Military Force Against Iraq H.R. 2529 / S. 2394 - Richard G. Lugar and Ellen O. Tauscher Act to Maintain Limits on Russian Nuclear Forces H.R. 4097 - Afghan Womens Inclusion in Negotiations (WIN) Act H.R. 4507 - The Protecting Saudi Dissidents Act to impose limits on arms sales to Saudi Arabia and require various reports and actions related to the death of Saudi Arabian journalist Jamal Khashoggi. H.R. 4986 - Green Climate Fund Authorization Act of 2019 H.R. 5543 - No War Against Iran Act H.R. 6089 - U.S.-Africa Strategic Security Act H.R. 6174 - Youth, Peace, and Security Act of 2020 H.R. 6581 - Robust International Response to Pandemic Act H.R. 6639 - No Unconstitutional War Against North Korea Act of 2020 H.R. 7500 To Limit Further Expansion of the 2001 Authorization for Use of Military Force, and for other purposes S.J. Res. 12 - To withdraw all United States Armed Forces from Afghanistan S.Res. 673 - A resolution affirming that the New START Treaty extension will cover new deployed Russian nuclear delivery systems S. 854 - Enhancing Human Rights Protections in Arms Sales Act of 2019 S. 1743 - International Climate Accountability Act S. 2394 - Richard G. Lugar and Ellen O. Tauscher Act to Maintain Limits on Russian Nuclear Forces S. 2953 - Ensuring a Durable Afghanistan Peace Act of 2019 S.3159 - No War Against Iran Act S.3314 - Iran Diplomacy Act of 2020 S.4139 - A bill to encourage support by international financial institutions for a robust global response to the COVID-19 pandemic. Unnumbered bill amending the War Powers Act, the Arms Export Control Act, and the National Emergencies Act Unnumbered bill to limit every statutory force authorization to two years Unnumbered bill to halt the Ground Based Strategic Deterrent program

Client expense: $1,000,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR 6674 Medicare Crisis Program 2020; S3864 Medicare Mental Health Inpatient Equity Act of 2020; HR6811 WIC Act 2020; HR 4618 Medicare Hearing Act; S1114 Medicare Adv Quality Payment Relief Act; HR4665 Medicare Vision Act; HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR 1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 Patient Protection and Affordable Care Enhance Act; S.3 Keeping Insurance Affordable of 2019; S470 Medicaid at 50 Act; S773 Telelhealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act;

Client expense: Not reported · Firm income: $15,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR6674 Medicare Crisis Program 2020; S3864 Medicare Mental Health Inpatient Equity Act of 2020; HR6811 WIC Act 2020; HR6445,S3563 Food Assistance for Kids and Families during COVID 2020.HR 6281, S3500 Medicare Wage Index Parity Act 2020; HR 4618 Medicare Hearing Act;HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 Patient Protection & Affordable Care Act; S470 Medicaid at 50 Act; S773 Telehealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.; S1114 Medicare Adv Quality Payment Relief Act; H.R.2564 Medicare Enrollment Protection Act; H.R.275 Medicare Prescription Drug Price Negotiation Act of 2019;H.R.884 Medicare Mental Health Access Act; H.R.3127 Medicare Home Health Flexibility Act; H.R.1384 Medicare for All Act of 2019.

Client expense: Not reported · Firm income: $11,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.Res. 152 - Calling for a formal end of the Korean war, all provisions. H.Res. 495 - Expressing the Sense of the House of Representatives regarding the Prevention of Iran from Obtaining or Developing Nuclear Weapons H.R. 1264 - To sunset the 2001 Authorization for Use of Military Force H.R. 2407 - Promoting Human Rights for Palestinian Children Living Under Israeli Military Occupation Act H.R. 2456 - To repeal the 2002 Authorization for Use of Military Force Against Iraq H.R. 2529 / S. 2394 - Richard G. Lugar and Ellen O. Tauscher Act to Maintain Limits on Russian Nuclear Forces H.R. 4097 - Afghan Womens Inclusion in Negotiations (WIN) Act H.R. 4507 - The Protecting Saudi Dissidents Act to impose limits on arms sales to Saudi Arabia and require various reports and actions related to the death of Saudi Arabian journalist Jamal Khashoggi. H.R. 4986 - Green Climate Fund Authorization Act of 2019 H.R. 5543 - No War Against Iran Act H.R. 6089 - U.S.-Africa Strategic Security Act H.R. 6174 - Youth, Peace, and Security Act of 2020 H.R. 6581 - Robust International Response to Pandemic Act H.R. 6639 - No Unconstitutional War Against North Korea Act of 2020 H.R. 7500 To Limit Further Expansion of the 2001 Authorization for Use of Military Force, and for other purposes S.J. Res. 12 - To withdraw all United States Armed Forces from Afghanistan S.J. Res. 68 - A joint resolution to direct the removal of United States Armed Forces from hostilities against the Islamic Republic of Iran that have not been authorized by Congress S.Res. 371 - A resolution reaffirming the support of the United States for the people of the Republic of South Sudan and calling on all parties to uphold their commitments to peace and dialogue as outlined in the 2018 revitalized peace agreement. S.Res. 509 - A resolution calling upon the United Nations Security Council to adopt a resolution on Iran that extends the dates by which Annex B restrictions under Resolution 2231 are currently set to expire. S.Res. 673 - A resolution affirming that the New START Treaty extension will cover new deployed Russian nuclear delivery systems S. 854 - Enhancing Human Rights Protections in Arms Sales Act of 2019 S. 1743 - International Climate Accountability Act S. 2394 - Richard G. Lugar and Ellen O. Tauscher Act to Maintain Limits on Russian Nuclear Forces S. 2953 - Ensuring a Durable Afghanistan Peace Act of 2019 S.3159 - No War Against Iran Act S.3314 - Iran Diplomacy Act of 2020 S.3176 - United States-Israel Security Assistance Authorization Act of 2020 S.4139 - A bill to encourage support by international financial institutions for a robust global response to the COVID-19 pandemic. Unnumbered bill amending the War Powers Act, the Arms Export Control Act, and the National Emergencies Act Unnumbered bill to limit every statutory force authorization to two years Unnumbered bill to halt the Ground Based Strategic Deterrent program

H.Res. 152 - Calling for a formal end of the Korean war, all provisions. H.Res. 495 - Expressing the Sense of the House of Representatives regarding the Prevention of Iran from Obtaining or Developing Nuclear Weapons H.R. 1264 - To sunset the 2001 Authorization for Use of Military Force H.R. 2407 - Promoting Human Rights for Palestinian Children Living Under Israeli Military Occupation Act H.R. 2456 - To repeal the 2002 Authorization for Use of Military Force Against Iraq H.R. 2529 / S. 2394 - Richard G. Lugar and Ellen O. Tauscher Act to Maintain Limits on Russian Nuclear Forces H.R. 4097 - Afghan Womens Inclusion in Negotiations (WIN) Act H.R. 4507 - The Protecting Saudi Dissidents Act to impose limits on arms sales to Saudi Arabia and require various reports and actions related to the death of Saudi Arabian journalist Jamal Khashoggi. H.R. 4986 - Green Climate Fund Authorization Act of 2019 H.R. 5543 - No War Against Iran Act H.R. 6089 - U.S.-Africa Strategic Security Act H.R. 6174 - Youth, Peace, and Security Act of 2020 H.R. 6581 - Robust International Response to Pandemic Act H.R. 6639 - No Unconstitutional War Against North Korea Act of 2020 H.R. 7500 To Limit Further Expansion of the 2001 Authorization for Use of Military Force, and for other purposes S.J. Res. 12 - To withdraw all United States Armed Forces from Afghanistan S.J. Res. 68 - A joint resolution to direct the removal of United States Armed Forces from hostilities against the Islamic Republic of Iran that have not been authorized by Congress S.Res. 371 - A resolution reaffirming the support of the United States for the people of the Republic of South Sudan and calling on all parties to uphold their commitments to peace and dialogue as outlined in the 2018 revitalized peace agreement. S.Res. 509 - A resolution calling upon the United Nations Security Council to adopt a resolution on Iran that extends the dates by which Annex B restrictions under Resolution 2231 are currently set to expire. S.Res. 673 - A resolution affirming that the New START Treaty extension will cover new deployed Russian nuclear delivery systems S. 854 - Enhancing Human Rights Protections in Arms Sales Act of 2019 S. 1743 - International Climate Accountability Act S. 2394 - Richard G. Lugar and Ellen O. Tauscher Act to Maintain Limits on Russian Nuclear Forces S. 2953 - Ensuring a Durable Afghanistan Peace Act of 2019 S.3159 - No War Against Iran Act S.3314 - Iran Diplomacy Act of 2020 S.3176 - United States-Israel Security Assistance Authorization Act of 2020 S.4139 - A bill to encourage support by international financial institutions for a robust global response to the COVID-19 pandemic. Unnumbered bill amending the War Powers Act, the Arms Export Control Act, and the National Emergencies Act Unnumbered bill to limit every statutory force authorization to two years Unnumbered bill to halt the Ground Based Strategic Deterrent program

Issues related to prescription drug coverage and pharmacy benefits H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1035: Prescription Drug Price Transparency Act H.R.5800: Ban Surprise Billing Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act S.1895: Lower Health Care Costs Act Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Prescription drug pricing transparency H.R.1264/S.801: Payment Commission Data Act H.R.2376/S.1227: Prescription Pricing for the People Act H.R.3223/S.1532 PBM Study Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.5304: PBM Transparency in Prescription Drug Costs Act S.476: C-THRU Act S.2543: Prescription Drug Pricing Reduction Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits H.R.19/S.3129:Lower Costs More Cures Act H.R.2279/S.2546: Safe Step Act H.R.6557: MAIL Act H.R.3: Lower Drug Costs Now Act S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act Executive Order on An America-First Healthcare Plan Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Access to prescription drugs during the coronavirus pandemic H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R.6557 MAIL Act H.R.6800: HEROES Act Generic and biosimilar utilization H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes (McKinley) Issues related to prescription drug patents and approval process H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act Issues related to coverage of prescription drugs in the commercial market S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.5304: PBM Transparency in Prescription Drug Costs Act H.R.5800: Ban Surprise Billing Act

Issues related to prescription drug coverage and pharmacy benefits H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1035: Prescription Drug Price Transparency Act H.R.5800: Ban Surprise Billing Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits H.R.19/S.3129: Lower Costs More Cures Act H.R. 2279/S.2546: Safe Step Act H.R.3: Lower Drug Costs Now Act H.R. 6557 MAIL Act S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act Executive Order on An America-First Healthcare Plan Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Prescription drug pricing transparency H.R.1264/S.801: Payment Commission Data Act H.R.223/S.532: PBM Study Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.5304: PBM Transparency in Prescription Drug Costs Act S.476: C-THRU Act S.2543: Prescription Drug Pricing Reduction Act Access to prescription drugs during the coronavirus pandemic H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R.6557: MAIL Act H.R.6800: HEROES Act Generic and biosimilar utilization H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes

Client expense: $2,676,362 · Firm income: Not reported

assist client with issues pertaining to medicare and medicaid. HR 6674 Medicare Crisis Program 2020; S3864 Medicare Mental Health Inpatient Equity Act of 2020; HR6811 WIC Act 2020; HR 4618 Medicare Hearing Act; S1114 Medicare Adv Quality Payment Relief Act; HR4665 Medicare Vision Act; HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR 1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 Patient Protection and Affordable Care Enhance Act; S.3 Keeping Insurance Affordable of 2019; S470 Medicaid at 50 Act; S773 Telelhealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act;

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR6674 Medicare Crisis Program 2020; S3864 Medicare Mental Health Inpatient Equity Act of 2020; HR6811 WIC Act 2020; HR6445,S3563 Food Assistance for Kids and Families during COVID 2020.HR 6281, S3500 Medicare Wage Index Parity Act 2020; HR 4618 Medicare Hearing Act;HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 Patient Protection & Affordable Care Act; S470 Medicaid at 50 Act; S773 Telehealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.; S1114 Medicare Adv Quality Payment Relief Act; H.R.2564 Medicare Enrollment Protection Act; H.R.275 Medicare Prescription Drug Price Negotiation Act of 2019;H.R.884 Medicare Mental Health Access Act; H.R.3127 Medicare Home Health Flexibility Act; H.R.1384 Medicare for All Act of 2019.

Client expense: Not reported · Firm income: $11,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug coverage and pharmacy benefits H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1035: Prescription Drug Price Transparency Act H.R.5800: Ban Surprise Billing Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act S.1895: Lower Health Care Costs Act Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Prescription drug pricing transparency H.R.1264/S.801: Payment Commission Data Act H.R.2376/S.1227: Prescription Pricing for the People Act H.R.3223/S.1532 PBM Study Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.5304: PBM Transparency in Prescription Drug Costs Act S.476: C-THRU Act S.2543: Prescription Drug Pricing Reduction Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits H.R.19/S.3129:Lower Costs More Cures Act H.R.2279/S.2546: Safe Step Act H.R.6557: MAIL Act H.R.3: Lower Drug Costs Now Act S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act Access to prescription drugs during the coronavirus pandemic H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R.6557 MAIL Act H.R.6800: HEROES Act Generic and biosimilar utilization H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes (McKinley) Issues related to prescription drug patents and approval process H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act Issues related to coverage of prescription drugs in the commercial market S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.5304: PBM Transparency in Prescription Drug Costs Act H.R.5800: Ban Surprise Billing Act

Issues related to prescription drug coverage and pharmacy benefits H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1035: Prescription Drug Price Transparency Act H.R.5800: Ban Surprise Billing Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits H.R.19/S.3129: Lower Costs More Cures Act H.R. 2279/S.2546: Safe Step Act H.R.3: Lower Drug Costs Now Act H.R. 6557 MAIL Act S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act S.3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act Prescription drug pricing transparency H.R.1264/S.801: Payment Commission Data Act H.R.223/S.532: PBM Study Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.5304: PBM Transparency in Prescription Drug Costs Act S.476: C-THRU Act S.2543: Prescription Drug Pricing Reduction Act Access to prescription drugs during the coronavirus pandemic H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R.6557: MAIL Act H.R.6800: HEROES Act Generic and biosimilar utilization H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes

Client expense: $1,173,453 · Firm income: Not reported

assist client with issues pertaining to medicare and medicaid. HR 6674 Medicare Crisis Program 2020; S3864 Medicare Mental Health Inpatient Equity Act of 2020; HR6811 WIC Act 2020; HR 4618 Medicare Hearing Act; S1114 Medicare Adv Quality Payment Relief Act; HR4665 Medicare Vision Act; HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR 1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State health Care Premium Reduction Act; S.3 Keeping Insurance Affordable of 2019; S470 Medicaid at 50 Act; S773 Telelhealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act;

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR6674 Medicare Crisis Program 2020; S3864 Medicare Mental Health Inpatient Equity Act of 2020; HR6811 WIC Act 2020; HR6445,S3563 Food Assistance for Kids and Families during COVID 2020.HR 6281, S3500 Medicare Wage Index Parity Act 2020; HR 4618 Medicare Hearing Act;HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State Healthcare Premium Reduction Act; S470 Medicaid at 50 Act; S773 Telehealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.; S1114 Medicare Adv Quality Payment Relief Act; H.R.2564 Medicare Enrollment Protection Act; H.R.275 Medicare Prescription Drug Price Negotiation Act of 2019;H.R.884 Medicare Mental Health Access Act; H.R.3127 Medicare Home Health Flexibility Act; H.R.1384 Medicare for All Act of 2019.

Client expense: Not reported · Firm income: $11,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug coverage and pharmacy benefits Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act H.R. 19/S.3129: Lower Costs More Cures Act H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.3: Lower Drug Costs Now Act H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes H.R.5304: PBM Transparency in Prescription Drug Costs Act H.R.5800: Ban Surprise Billing Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act S.3130: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act

Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.19/S.3129: Lower Costs More Cures Act H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.3: Lower Drug Costs Now Act H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes H.R.5304: PBM Transparency in Prescription Drug Costs Act H.R.5800: Ban Surprise Billing Act S.476: C-THRU Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act S.3130: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S.3384: Lowering Prescription Drug Prices for America's Seniors and Families Act

Client expense: $1,069,799 · Firm income: Not reported

assist client with issues pertaining to medicare and medicaid. HR 4618 Medicare Hearing Act; S1114 Medicare Adv Quality Payment Relief Act; HR4665 Medicare Vision Act; HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR 1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State health Care Premium Reduction Act; S.3 Keeping Insurance Affordable of 2019; S470 Medicaid at 50 Act; S773 Telelhealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR 4618 Medicare Hearing Act;HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State Healthcare Premium Reduction Act; S470 Medicaid at 50 Act; S773 Telehealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.; S1114 Medicare Adv Quality Payment Relief Act; H.R.2564 Medicare Enrollment Protection Act; H.R.275 Medicare Prescription Drug Price Negotiation Act of 2019;H.R.884 Medicare Mental Health Access Act; H.R.3127 Medicare Home Health Flexibility Act; H.R.1384 Medicare for All Act of 2019.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.3: Lower Drug Costs Now Act H.R. 4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes S.476: C-THRU Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act

Client expense: $1,257,921 · Firm income: Not reported

Issues related to prescription drug coverage and pharmacy benefits Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.3: Lower Drug Costs Now Act H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act

assist client with issues pertaining to medicare and medicaid. HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR 1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State health Care Premium Reduction Act; S-3 Keeping Insurance Affordable of 2019; S470 Medicaid at 50 Act; S773 Telelhealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State Healthcare Premium Reduction Act; S470 Medicaid at 50 Act; S773 Telehealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.; H.R.2564 Medicare Enrollment Protection Act; H.R.275 Medicare Prescription Drug Price Negotiation Act of 2019;H.R.884 Medicare Mental Health Access Act; H.R.3127 Medicare Home Health Flexibility Act; H.R.1384 Medicare for All Act of 2019.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Provisions related to price transparency rebates and spread pricing; Provisions related to pharmacist direct and indirect remuneration; The Prescription Drug Price Transparency Act (H.R. 1035); The Phair Pricing Act (S. 640/H.R. 1034); The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act (S. 476); The Payment Commission Data Act (S. 801/HR 1264, H.R. 1781); Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (H.R. 803); Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019 (H.R. 2113).

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2113: "The Prescription Drug STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment.

S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2113: "The Prescription Drug STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. S.2543: The Prescription Drug Pricing Reduction Act (PDPRA) of 2019, -Legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drugs. Provisions related to inflation protection provisions and PBM transparency. S.2247: Phair Relief Act, Provisions related to pharmacy DIR. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment. CMS Proposed rule: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," (CMS-4180-P)-provisions related to pharmacy Direct and Indirect Negotiation.

Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.3: Lower Drug Costs Now Act S.476: C-THRU Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act

Client expense: $854,535 · Firm income: Not reported

Issues related to prescription drug coverage and pharmacy benefits Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781: Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act H.R.3: Lower Drug Costs Now Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act S.2543: Prescription Drug Pricing Reduction Act S.2247: Phair Relief Act

assist client with issues pertaining to medicare and medicaid. HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State Healthcare Premium Reduction Act; S470 Medicaid at 50 Act; S773 Telehealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.; H.R.2564 Medicare Enrollment Protection Act; H.R.275 Medicare Prescription Drug Price Negotiation Act of 2019;H.R.884 Medicare Mental Health Access Act; H.R.3127 Medicare Home Health Flexibility Act; H.R.1384 Medicare for All Act of 2019.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR 1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State health Care Premium Reduction Act; S-3 Keeping Insurance Affordable of 2019; S470 Medicaid at 50 Act; S773 Telelhealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Provisions related to price transparency rebates and spread pricing; Provisions related to pharmacist direct and indirect remuneration; The Prescription Drug Price Transparency Act (H.R. 1035); The Phair Pricing Act (S. 640/H.R. 1034); The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act (S. 476); The Payment Commission Data Act (S. 801/HR 1264, H.R. 1781); Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (H.R. 803); Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019 (H.R. 2113).

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. S.2543: The Prescription Drug Pricing Reduction Act (PDPRA) of 2019, -Legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drugs. Provisions related to inflation protection provisions and PBM transparency. S.2247: Phair Relief Act, Provisions related to pharmacy DIR. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment. CMS Proposed rule: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," (CMS-4180-P)-provisions related to pharmacy Direct and Indirect Negotiation.

HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment.

Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act S.476: C-THRU Act H.R.1035: Prescription Drug Price Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act

Client expense: $643,224 · Firm income: Not reported

Issues related to prescription drug coverage and pharmacy benefits Issues included in the Administrations drug pricing Blueprint Issues related to HHS OIG Proposed Rule 42 CFR Part 1001 RIN 0936-AA08; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees Issues related to CMS Proposed Rule 42 CFR Parts 422 and 423 RIN 0938-AT92; Modernizing Part D and Medicare Advantage To Lower Out-of-Pocket Expenses Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market Issues related to the affordability of prescription drugs and competitive marketplace, including: pedigree, manufacturer market and data exclusivity, REMS, accelerated generic approval, biosimilars H.R.803/S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act H.R.1034/S.640: Phair Pricing Act of 2019 H.R.1264/S.801: Payment Commission Data Act H.R.965/S.340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act H.R.2376/S.1227: Prescription Pricing for the People Act S.476: C-THRU Act S.64: Preserve Access to Affordable Generics and Biosimilars Act S.659: Biologic Patent Transparency Act S.657: Drug Price Transparency Act S.977: Transparent Drug Pricing Act S.1895: Lower Health Care Costs Act H.R.1035: Prescription Drug Price Transparency Act H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act H.R.985: Fair Access for Safe and Timely (FAST) Generics Act H.R.1499: Protecting Consumer Access to Generic Drugs Act H.R.1520: Purple Book Continuity Act H.R.1503: Orange Book Transparency Act H.R.1781 Payment Commission Data Act H.R.2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H.R.2115: Public Disclosure of Drug Discounts Act

assist client with issues pertaining to medicare and medicaid. HR259 Medicaid Extender Act 2019; HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR 1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State health Care Premium Reduction Act; S-3 Keeping Insurance Affordable of 2019; S470 Medicaid at 50 Act; S773 Telelhealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR 259 Medicaid Extender Act 2019; HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State Healthcare Premium Reduction Act; S470 Medicaid at 50 Act; S773 Telehealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.; H.R.2564 Medicare Enrollment Protection Act; H.R.275 Medicare Prescription Drug Price Negotiation Act of 2019;H.R.884 Medicare Mental Health Access Act; H.R.3127 Medicare Home Health Flexibility Act; H.R.1384 Medicare for All Act of 2019.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Provisions related to price transparency rebates and spread pricing; Provisions related to pharmacist direct and indirect remuneration; The Prescription Drug Price Transparency Act (H.R. 1035); The Phair Pricing Act (S. 640/H.R. 1034); The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act (S. 476); The Payment Commission Data Act (S. 801/HR 1264, H.R. 1781); Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (H.R. 803); Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019 (H.R. 2113).

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1897 MOMMA's Act - Federal efforts with respect to the prevention of maternal mortality H.R.2115 Public Disclosure of Drug Discounts Act - legislation to provide greater transparency of discounts provided by drug manufacturers. S.340/H.R.965 CREATES - facilitate the timely entry of lower-cost generic and biosimilar versions of drugs and biological products H.R. 938 the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019 - eligibility for FDA approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval H.R. 1520, the Purple Book Continuity Act of 2019; publication of a list of licensed biological products H.R. 1503, the Orange Book Transparency Act of 2019; list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, H.R. 1781 Payment Commission Data Act of 2019 - provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information H.R. 1264 Payment Commission Data Act of 2019 - provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019 - pay for delay; prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products H.R.2113 Prescription Drug STAR Act - require drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, H.R.2296, S.1391 FAIR Drug Pricing Act - Rx pricing transparency, require manufacturers to justify price increases H.R.2376, S.1227 Prescription Pricing for the People Act - directs the Federal Trade Commission to report to Congress on the effect of certain anticompetitive practices in the pharmaceutical supply chain S.Res.134 - A resolution expressing the sense of the Senate that the Department of Justice should reverse its position in Texas v. United States, No. 4:18-cv-00167-O (N.D. Tex.) H.R.1010 - To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect H.Res.356 - Expressing support for Designation of May as "National Asthma and Allergy Awareness Month" H.R.1868 - Health Care Affordability Act of 2019 - reducing insurance premiums and out-of-pocket costs in the individual and small group markets, both for low-income families and those that are not eligible for tax credits H.R.1385 State Allowance for a Variety of Exchanges (SAVE) Act - preserve the option of States to implement health care marketplaces H.R.1386 ENROLL Act - amending ACA with new Navigator program requirements H.R.1425 State Health Care Premium Reduction Act - Improve Health Insurance Affordability Fund to provide for certain reinsurance payments to lower premiums in the individual health insurance market S.1213 Consumer Health Insurance Protection Act - - comprehensive insurance reform proposals including provisions pegging consumer assistance to plans with higher actuarial value, lowering out-of-pocket maximums, extending eligibility for subsidies, fixing family glitch, investing in enrollment outreach, requiring insurers to cover emergency services at in-network costs, making short-term limited duration plans subject to ACAs consumer protections H.R.986 - Protecting Americans with Preexisting Conditions Act of 2019 - certain guidance related to waivers for State innovation under the Patient Protection and Affordable Care Act shall have no force or effect H.R.2569, S.1365 Comprehensive Addiction Resources Emergency Act of 2019 - provide emergency assistance to States, territories, Tribal nations, and local areas affected by the opioid epidemic and to make financial assistance available to States, territories, Tribal nations, local areas, and public or private nonprofit entities to provide for the development, organization, coordination, and operation of more effective and cost efficient systems for the delivery of essential services to individuals with substance use disorder and their families H.R.987 Strengthening Health Care and Lowering Prescription Drug Costs Ac- requires the Department of Health and Human Services (HHS) to conduct outreach and educational activities regarding federally-facilitated exchanges (i.e., health insurance exchanges that are established and operated within states by HHS). The activities must inform potential enrollees of the availability of coverage and related financial assistance under the exchanges and must be provided in culturally and linguistically appropriate formats. S.1556 No Junk Plans Act - rule entitled Short-Term, Limited Duration Insurance shall have no force or effect. S.1531 STOP Surprise Medical Bills Act - provide protections for health insurance consumers from surprise billing H.R.861 - End Surprise Billing Act of 2019 - prevent surprise billing practices and require notification for consumers Lower Health Care Costs Act - comprehensive legislation to end surprise medical bills, reduce prescription drug prices, improve health care transparency, improve public health, improve exchange of health information No Surprises Act - legislation to protect consumers from surprise medical bills Protecting People From Surprise Medical Bills Act - legislation to protect consumers from surprise medical bills, arbitration as payment mechanism H.R.2075,S.1013 School-Based Health Center Reauthorization Act - reauthorize school-based health centers S.1737 Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits H.R.748, S. 684 Middle Class Health Benefits Tax Repeal Act of 2019 - repeal the excise tax on high value employer-sponsored health care coverage, also known as the Cadillac Tax S.1935 Family Coverage Act - fix ACAs family glitch S. 1801 Affordable Medications Act - increase drug price transparency and affordability, spur innovation, and enhance competition S.455/ H.R.987 - MORE Health Education Act - funding for Federal Exchange outreach and educational activities H.R.3180, S. 1770 RISE (Resilience Investment, Support, and Expansion) from Trauma Act - improve the identification and support of children and families who experience trauma Draft legislation on patent evergreening Legislation to reauthorize the Patient-Centered Outcomes Research Institute (PCORI)

Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Request for information: "HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs," provisions affecting market competition for prescription drugs and the drug supply chain. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act, eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1497: Health Care Price Check Act of 2019, requires Medicare and insurance companies to make available an online tool and a toll-free # for beneficiaries to inquire about the cost, for that specific consumer, of any services, procedure or product including prescription drugs. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs.

S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act, issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act, issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information--Provisions on Part D. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P as in proposed and final version CMS-4182-F, particularly issues related to pharmacy DIR and implementation of a real-time-benefit tool); provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies." HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act, eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1497: Health Care Price Check Act of 2019, requires Medicare and insurance companies to make available an online tool and a toll-free # for beneficiaries to inquire about the cost, for that specific consumer, of any services, procedure or product including prescription drugs. S. 64: Preserve Access to Affordable Generics and Biosimilars Act, bars pay-for-delay for generics and biosimilars. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1505: a bill to require prescription drug plans and MA-PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (Provisions requiring GAO to submit a report on PBMs). Modernization and cost-sharing of the Part D drug benefit. H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2087: "The STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019, FTC study of PBMs.

S. 708 Regulatory Improvement Act (Establishes in the legislative branch the Regulatory Improvement Commission.) S.774 Financial Institutions Examination Fairness and Reform Act (Amends the Federal Financial Institutions Examination Council Act of 1978 to require a federal financial institutions regulatory agency to make a final examination report to a financial institution within 60 days of the later of: (1) the exit interview for an examination of the institution, or (2) the provision of additional information by the institution relating to the examination.) S. 1484 Financial Regulatory Improvement Act of 2015 (This bill amends the Gramm-Leach-Bliley Act to exempt from the requirement to provide consumers with an annual written disclosure of their privacy policy certain financial institutions that provide nonpublic personal information to a nonaffiliated third party to perform services for or functions on behalf of the financial institution.) S.1491 Community Lender Regulatory Relief and Consumer Protection Act of 2015 (Bill amends the Truth in Lending Act, Gramm0Leach Bliley Act, FDI Act, FHLB Act, and the Securities Exchange Act)S.1607 the Independent Agency Regulatory Analysis Act of 2015 (A bill to affirm the authority of the President to require independent regulatory agencies to comply with regulatory analysis requirements applicable to executive agencies, and for other purposes.)S. 1647 Developing a Reliable and Innovative Vision for the Economy Act (To amend title 23, United States Code, to authorize funds for Federal-aid highways and highway safety construction programs, and for other purposes.) S. 1773 Consumer Reporting Fairness Act of 2015 (To amend title 11, United States Code, to require creditors to inform consumer reporting agencies that certain debts discharged in bankruptcy cases.)S. 1818 Principled Rulemaking Act (This bill revises the federal agency rulemaking process to require a agencies to promulgate only rules (defined to exclude agency actions involving a military or foreign affairs function of the United States or a matter relating to agency management or personnel or to public property, loans, grants, benefits, or contracts) that are required by law, necessary to interpret a law, or made necessary by public need, to protect or improve the health and safety of the public, the environment, or the wellbeing of the people of the United States.)S. 1820 Early Participation in Regulations Act (he bill directs an agency, not later than 90 days before publishing a notice of proposed rule making for a major rule in the Federal Register, to publish advance notice of proposed rule making S. 1817 Smarter Regulations Through Advance Planning and Review Act ( This bill requires a federal agency, when publishing a proposed major rule and when publishing a final major rule, to include a framework for assessing the rule)S. 1958 Christopher Bryski Student Loan Protection Act (To establish additional protections and disclosures for students and co-signers with respect to student loans) S. 2038 Jumpstart GSE reform Act (prohibits the use of an increase in the guarantee fee required to be charged by the Federal National Mortgage Association (Fannie Mae), the Federal Home Loan Mortgage Corporation (Freddie Mac), or any affiliate of such organizations (enterprises) to offset increase in outlays or a reduction in revenues for purposes other than those related to enterprises' business functions) S. 2663 Reforming CFPB Indirect Auto Financing Guidance Act (This bill declares without force or effect Consumer Financial Protection Bureau (CFPB) Bulletin 2013-02 (Indirect Auto Lending and Compliance with the Equal Credit Opportunity Act), published March 21, 2013.) S.J. Res. 19 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of rule submitted by Bureau of Consumer Financial Protection on prepaid accounts under the Electronic Fund Transfer Act and the Truth in Lending Act. (CRA) S. 552: Justice for Victims of Fraud Act (This bill amends the Truth in Lending Act and the Electronic Fund Transfer Act to prohibit predispute arbitration agreements with consumers (i.e., agreements to arbitrate any future disputes between parties instead of pursuing the claims in court) from being valid or enforceable in disputes related to credit card accounts or personal bank accounts that are not subject to a final judgment by a court if credit card or bank account was not issued in response to a request or application for that account.) S. 537: Arbitration Fairness Act (This bill prohibits a predispute arbitration agreement from being valid or enforceable if requires arbitration of aemployment, consumer, antitrust, or civil rights dispute.) S.550: Restoring Statutory Rights and Interests of the States Act (This bill amends the Federal Arbitration Act to invalidate arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution, unless the written agreement to arbitrate is entered into by both parties after the claim has arisen and pertains solely to an existing claim.)S.553: Court Legal Access and Student Support (CLASS) Act (This bill makes procedures for the enforcement of arbitration agreements inapplicable to enrollment agreement between student and an institution of higher education (IHE).) S. 647: Mandatory Arbitration Transparency Act (This bill prohibits predispute arbitration agreements from containing a confidentiality clause regarding an employment, consumer, or civil rights dispute that could be interpreted to prohibit a party from: (1) making a communication in a manner such that prohibition would violate a whistle-blower statute; or (2) reporting or making communication about tortious conduct, unlawful conduct, or issues of public policy or public concern. )S. 646: Justice for Servicemembers Act (This bill authorizes the Department of Justice (DOJ) to initiate an action for relief in a service member's employment or reemployment rights action: (1) a private or state employer, or (2) a state or private employer that is engaged in a pattern or practice to infringe upon such rights.) S.867 - PROTECT Students Act of 2019 ; To protect students of institutions of higher education and taxpayer investment in institutions of higher education by improving oversight and accountability of institutions of higher education, particularly for-profit colleges, improving protections for students and borrowers, and ensuring the integrity of postsecondary education programs, and for other purposesS.951 - Regulatory Accountability Act of 2017 (This bill codifies and revises notice-and-comment rulemaking procedures to require federal agencies to consider: (1) whether a rulemaking is required by statute or is within the discretion of the agency, (2) whether existing federal laws or rules could be amended or rescinded to address the problem, and (3) reasonable alternatives for a new rule.) S.1642, Protecting Consumers Access to Credit Act of 2017 (This bill amends the Revised Statutes, the Home Owners' Loan Act, the Federal Credit Union Act, and the Federal Deposit Insurance Act to state that bank loans that are valid when made as to their maximum rate of interest in accordance with federal law shall remain valid with respect to that rate regardless of whether a bank has subsequently sold or assigned the loan to a third party. S.J.Res.47 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of rule submitted by Bureau of Consumer Financial Protection on "Arbitration Agreements" S.1659, the Protecting Consumers from Unreasonable Credit Rates Act (This bill amends the Truth in Lending Act to prohibit a creditor from extending credit to a consumer under an open end consumer credit plan (credit card) for which the fee and interest rate exceeds 36%.) S.2155, Economic Growth, Regulatory Relief, and Consumer Protection Act (bill aimed at rolling back financial regulations concerning banks other financial institutions) S.J.Res57 A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to "Indirect Auto Lending and Compliance with the Equal Credit Opportunity Act"H.R. 4, makes revisions to Federal law to improve the conditions necessary for economic growth and job creation, and for other purposes.H.R. 37, makes technical corrections to the Dodd-Frank Wall Street Reform and Consumer Protection Act, to enhance the ability of small and emerging growth companies to access capital through public and private markets, to reduce regulatory burdens, and for other purposes.H.R. 50, provides for additional safeguards with respect to imposing Federal mandates, other purposes. H.R113, improves the accountability and transparency of the Board of Governors of the Federal Reserve System, and for other purposes. H.R185, reforms the process by which Federal agencies analyze and formulate new regulations and guidance documents. H.R.347, amends the Credit Repair Organizations Act to exempt certain consumer reporting agencies, and for other purposes.H.R. 367, amends chapter 8 of title 5, United States Code, to provide that major rules of the executive branch shall have no force or effect unless a joint resolution of approval is enacted into law.H.R. 427, amends chapter 8 of title 5, United States Code, to provide that major rules of the executive branch shall have no force or effect unless a joint resolution of approval is enacted into law.H.R. 527, amends chapter 6 of title 5, United States Code (Regulatory Flexibility Act), to ensure complete analysis of potential impacts on small entities of rules, and for other purposes.H.R. 650, amends the Truth in Lending Act to modify the definitions of a mortgage originator and a high-cost mortgage.H.R.685, amends the Truth in Lending Act to improve upon the definitions provided for points and fees in connection with a mortgage transaction.H.R.766, provides requirements for the appropriate Federal banking agencies when requesting or ordering a depository institution to terminate a specific customer account, to provide for additional requirements related to subpoenas issued under the Financial Institutions Reform, Recovery, and Enforcement Act of 1989, and for other purposes.H.R. 899, provides for additional safeguards with respect to imposing Federal mandates, other purposes.H.R. 957, requires Senate confirmation of Inspector General of the Bureau of Consumer Financial Protection, and for other purposes.H.R. 1090, amends the Securities Exchange Act of 1934 to provide protections for retail customers, and for other purposes.H.R. 1195, amends the Consumer Financial Protection Act of 2010 to establish advisory boards, and for other purposesH.R. 1210, amends the Truth in Lending Act to provide a safe harbor from certain requirements related to qualified mortgages for residential mortgage loans held on an originating depository institution's portfolio, and for other purposes.H.R. 1259, provides for an application process for interested parties to apply for an area to be designated as a rural area, and for other purposes.H.R. 1261, amends the Consumer Financial Protection Act of 2010 to bring the Bureau of Consumer Financial Protection into the regular appropriations process,H.R1264, provides an exemption from rules and regulations of the Bureau of Consumer Financial protection for community financial institutions, H.R.1265, applies the requirements of the Federal Advisory Committee Act to the Bureau of Consumer Financial Protection.H.R.1266, amends the Consumer Financial Protection Act of 2010 to make the Bureau of Consumer Financial Protection an independent Financial Product Safety Commission, other purposes.H.R. 1413, terminates Operation Choke Point.H.R.1493, imposes certain limitations on consent decrees and settlement agreements by agencies that require the agencies to take regulatory action in accordance with the terms thereof, and for other purposes.H.R.1529, amends the Truth in Lending Act and the Real Estate Settlement Procedures Act of 1974 to modify the requirements for community financial institutions with respect to certain rules relating to mortgage loans, and for other purposes. H.R.1553 amends the Federal Deposit Insurance Act to specify which smaller institutions may qualify for an 18-month examination cycle. H.R.1660, amends the Home Owners' Loan Act to allow Federal savings associations to elect to operate as national banks, H.R. 1737, nullifies certain guidance of the Bureau of Consumer Financial Protection and to provide requirements for guidance issued by the Bureau with respect to indirect auto lending. H.R1799, amends the Real Estate Settlement Procedures Act of 1974 to prohibit certain financial benefits for referrals of business and to improve the judicial relief for certain violations, other purposes. H.R. 1941, improves the examination of depository institutions, other purposes. H.R.2213, provides for a temporary safe harbor from the enforcement of integrated disclosure requirements for mortgage loan transactions under the Real Estate Settlement Procedures Act of 1974 and the Truth in Lending Act, H.R. 2243 suspends the current compensation packages for the senior executives of Fannie Mae and Freddie Mac and establish compensation for such positions in accordance with rates of pay for senior employees in the Executive Branch of the Federal Government, other purposes. H.R. 2354, directs Securities and Exchange Commission to review all its significant regulations to determine such regulations are necessary in the public interest or whether such regulations should be amended or rescinded. H.R.4294, amends the Internal Revenue Code of 1986 to ensure that retirement investors receive advice in their best interests, other purposes. H.R. 2542 amends chapter 6 of title 5, United States Code (commonly known as the Regulatory Flexibility Act), to ensure colete analysis of potential impacts on small entities of rules H.R.2683, amends the Fair Credit Reporting Act to delay the inclusion in consumer credit reports and to establish requirements for debt collectors with respect to medical debt information of veterans due to inappropriate or delayed billing payments or reimbursements from the Department of Veterans Affairs, and for other purposes.H.R. 2577, makes appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2016, and for other purposes.H.R. 2804, amends title 5, United States Code, to require the Administrator of the Office of Information and Regulatory Affairs to publish information about rules on the Internet other purposes. H.R. 3035, amends the Fair Credit Reporting Act to clarify Federal law with respect to reporting certain positive consumer credit information to consumer reporting agencies, other purposes. H.R. 3189. amends the Federal Reserve Act to establish requirements for policy rules and blackout periods of the Federal Open Market Committee, to establish requirements for certain activities of the Board of Governors of the Federal Reserve System, and to amend title 31, United States Code, to reform the manner in which the Board of Governors of the Federal Reserve System is audited H.R. 3192, provides for a temporary safe harbor from the enforcement of integrated disclosure requirements for mortgage loan transactions under the Real Estate Settlement Procedures Act of 1974 and the Truth in Lending ActH.R. 3438, amends title 5, United States Code, to postpone the effective date of high-impact rules H.R. 3634, establishes student loan borrowers' rights to basic consumer protections, reasonable flexible repayment options, access to earned credentials, and effective loan cancellation in exchange for public service H.R 4018 amends the Truth in Lending Act to establish deferred presentment transaction requirements, other purposes. H.R. 4293 amends the Employee Retirement Income Security Act of 1974 to ensure that retirement investors receive advice in their best interests, H.R. 4439, amends the Revised Statutes, the Bank Service Company Act, the Federal Deposit Insurance Act, and the Home Owners' Loan Act to clarify that the role of the insured depository institution as lender and the location of an insured depository institution under applicable law are not affected by any contract between institution and a third-party service provider, and to clarify that Federal preemption of State usury laws applies to any loan to which an insured depository institution is the party to which the debt is initially owed according to its terms, other purposes. H.R. 4550, amends the Fair Debt Collection Practices Act to exclude law firms and licensed attorneys who are engaged in activities related to legal proceedings from definition of a debt collector, to amend the Consumer Financial Protection Act of 2010 to prevent the Bureau of Consumer Financial Protection from exercising supervisory or enforcement authority with respect to attorneys H.R. 4725, amends the Federal Deposit Insurance Act to require short form call reports for certain depository institutions. H.R. 4768, amends title 5, United States Code, to clarify the nature of judicial review of agency interpretations of statutory, regulatory provisions. H.R. 5143, provides greater transparency and congressional oversight of international insurance standards setting processes, other purposes. H.R. 5485, makes appropriations for financial services and general government for the fiscal year ending September 30, 2017,other purposes. H.R. 5982, amends chapter 8 of title 5, United States Code, to provide for en bloc consideration in resolutions of disapproval for "midnight rules" Fiscal Year 2016 spending bills for the Department of Justice (CJS) Makes appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2016, and other purposes. Fiscal Year 2016 spending bills for the Department of Housing and Urban Development (THUD), Bill will fund critical infrastructure and safety programs, provide responsible levels of funding for low-income housing H.R. 21 -Midnight Rules Relief Act of 2017, amends chapter 8 of title 5, United States Code H.R. 26 -Executive Need of Scrutiny Act of 2017 (REINS Act), amends chapter 8 of title 5, United States Code, to provide that major rules of the executive branch shall have no force or effect unless a joint resolution of approval is enacted into law. H.R. 5 -Regulatory Accountability Act of 2017 (RAA), reforms the process by which Federal agencies analyze and formulate new regulations and guidance documents, to clarify the nature of judicial review of agency interpretations, to ensure complete analysis of potential impacts on small entities of rules, other purposes.H.J. Res. 73 - Providing congressional disapproval under chapter 8 of title 5, United States Code, of rule submitted by the Bureau of Consumer Financial Protection relating to prepaid accounts H.R. 1424, amends the Truth in Lending Act and the Electronic Fund Transfer Act to provide justice to victims of fraud. H.R. 1374, amends title 9 of the United States Code with respect to arbitration.H.R. 1396, restores statutory rights to the people of the United States from forced arbitration.H.R. 985, amends the procedures used in Federal court class actions and multidistrict litigation proceedings to assure fairer, more efficient outcomes H.R. 585, amends the Securities Exchange Act of 1934 to prohibit mandatory pre-dispute arbitration agreements, and for other purposes. H.R. 864, (Rep. Love), amends the Fair Debt Collection Practices Act to restrict the debt collection practices of certain debt collectors H.R. 924, (Rep. Rothfus), amends the Federal Financial Institutions Examination Council Act of 1978 to establish a three-judge independent examination review panel.H.R. 1457, (Rep. Tipton), the Making Online Banking Initiation Legal and Easy Act of 2017 (To establish requirements using a driver's license or personal identification card by certain financial institutions for opening an account or obtaining a financial product or service, and for other purposes.)H.R. 2133, (Rep. Luetkemeyer), the Community Lending Enhancement and Regulatory Relief Act of 2017 (CLEARR act) (To provide regulatory relief to community financial institutions, and for other purposes.) H.R. 2226, (Rep. Barr), the Portfolio Lending and Mortgage Access Act ( This bill amends the Truth in Lending Act to allow a depository institution or credit union with assets below a specified threshold to forgo certain ability-to-pay requirements regarding residential mortgage loans) H.R. 2396, (Rep. Trott), the Privacy Notification Technical Correction Act (Bill amends section 503 of the Gramm-Leach Bliley Act. H.R. 3221, (Rep. Kustoff), the Access to Affordable Mortgages Act of 2017 (Sec. 2) This bill amends the Truth in Lending Act and the Financial Institutions Reform, Recovery, Enforcement Act of 1989 to exempt from property appraisal requirements a mortgage loan of $250,000 or less if it appears on the loan creditor's balance sheet for at least three years.) H.R. 6792 -Consumers First Act -Draft bill H.R. _ To amend the Economic Growth, Regulatory Relief, and Consumer Protection Act to clarify seasoning requirements for certain refinanced mortgage loans, and for other purposes -H.R. 134 - To amend title 11 of the United States Code with respect to modification of certain mortgages on principal residences H.R._, (Rep. Hollingsworth), the Ensuring Quality Unbiased Access to Loans Act of 2017 (nullify certain guidance on deposit advance products and to amend the Federal Deposit Insurance Act to provide the appropriate Federal banking agencies with additional requirements H.R. _, (Rep. Tenney), to simplify the process for national banks to obtain deposit insurance,House Appropriations Financial Services and General Government Financial Services Bill H.R1116, Taking Account of Institutions with Low Operation Risk (TAILOR) Act of 2017 (This bill requires federal financial regulatory agencies to: (1) tailor any regulatory actions so as to limit burdens on the institutions involved, with consideration of the risk profiles and business models of those institutions; and (2) report to Congress on specific actions taken to do so, related issues) H.R. 1699, Preserving Access to Manufactured Housing Act of 2017 (This bill amends the Truth in Lending Act to specify that a retailer of manufactured housing is generally not a "mortgage originator" subject to requirements under that Act. Similarly, the bill amends the Secure and Fair EnforcementMortgage Licensing Act of 2008 to specify such a retailer is generally not a "loan originator" subject to requirements under Act.)H.R. 2954, Home Mortgage Disclosure Adjustment Act (amends Home Mortgage Disclosure Act of 1975 H.R. 3299, Protecting Consumers Access to Credit Act of 2017 (This bill amends the Revised Statutes, the Home Owners' Loan Act, H.R. 3791, Community Institution Mortgage Relief Act of 2017 (This bill amends the Truth inH.J.Res.111, Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection on arbitration H.R. 3760, the Protecting Consumers from Unreasonable Credit Rates Act (This bill amends the Truth in Lending Act to prohibit a creditor from extending credit to a consumer under an open end consumer credit plan (credit card) for which the fee and interest rate exceeds 36%.) H.R. 1153, the Mortgage Choice Act This bill amends the Truth in Lending Act to specify that neither escrow charges for insurance nor affiliated title charges shall be considered "points and fees" for purposes of determining whether a mortgage is a "high-cost mortgageH.R. 3978, the TRID Improvement Act ( This bill specifies that the amount deposited in the Securities and Exchange Commission (SEC) Reserve Fund for FY2018 may not exceed $48 million.) H.R. 6972, the Consumers First Act: To require the Consumer Financial Protection Bureau to meet its statutory purpose, and for other purposes. H.J.Res. 122 Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Consumer Financial Protection relating to "Payday, Vehicle Title, and Certain High-Cost Installment Loans

assist client with issues pertaining to medicare and medicaid. HR 259 Medicaid Extender Act 2019; HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR1390 Mobile Health Record Act; HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State Healthcare Premium Reduction Act; S470 Medicaid at 50 Act; S733 Telehealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

assist client with issues pertaining to medicare and medicaid. HR259 Medicaid Extender Act 2019; HR913 Clinical Treatment Act 2019; HR1264 Payment Commission Data Act 2019; HR 1390 Mobile Health Record Act;HR1394 Medigap Consumer Protection 2019; HR1409 Transparency in all Healthcare Pricing Act 2019; HR1425 State health Care Premium Reduction Act; S-3 Keeping Insurance Affordable of 2019; S470 Medicaid at 50 Act; S733 Telelhealth Innovation and Improvement Act; S377 Medicare Negotiation and Competitive Licensing Act 2019; S618 Medicare Choices Empowerment and Protection Act.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Provisions affecting market competition for prescription drugs and the drug supply chain; HHS Blueprint to lower drug prices and reduce out-of-pocket costs; The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/HR 965); The Phair Pricing Act (S. 640/HR 1034); Preserve Access to Affordable Generics and Biosimilars Act (S. 64); The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act (S. 476); Drug Price Transparency Act (S. 657); The Payment Commission Data Act (S. 801/HR 1264, HR 1781); Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (HR 803); The Prescription Drug Price Transparency Act (HR 1035); Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Provisions affecting market competition for prescription drugs and the drug supply chain; provisions related to rebates at the point of sale; provisions related to pharmacist direct and indirect remuneration; HHS Blueprint to lower drug prices and reduce out-of-pocket costs; Improving Access to Affordable Prescription Drugs Act (S 771/HR 1776); The Prescription Drug Price Transparency Act (HR 1316); The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 340/HR 965); The Phair Pricing Act (S. 640/HR 1034); Preserve Access to Affordable Generics and Biosimilars Act (S. 64); The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act (S. 476); Drug Price Transparency Act (S. 657); The Payment Commission Data Act (S. 801/HR 1264, HR 1781); Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (HR 803);The Prescription Drug Price Transparency Act (HR 1035); Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1316: The Prescription Drug Price Transparency Act--issues related to ensuring the continuity of MAC pricing. Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program Proposed Rule & Request for Information --Provisions on Part D. Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain. CMS Proposed and Final Policy Changes and Updates for Medicare Advantage and the Prescription Drug Benefit Program for Contract Year 2019 (CMS-4182-P), provisions in a Request for Information related to rebates at the point-of-sale and pharmacist direct and indirect renumeration. Proposed HHS-OIG rule currently under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection, RIN-936-AAO8. (See https://www.reginfo.gov/public/do/eoReviewSearch for questions). Outreach and education on pharmacy Direction and Indirection Remuneration in Medicare. Provisions related to opening the Medicare doughnut hole in P.L. 115-123. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act Pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act. S 64: Preserve Access to Affordable Generics and Biosimilars Act - Prohibits brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act - eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act H.R. 1264 and H.R. 1781 and S. 801 - Provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information.

Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Request for information: "HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs," provisions affecting market competition for prescription drugs and the drug supply chain. HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act Pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act. S 64: Preserve Access to Affordable Generics and Biosimilars Act - Prohibits brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. S 476: The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. S 657: Drug Price Transparency Act - eliminates rebates in ERISA plans. Proposed Rule: Fraud and Abuse: Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HHSIG-2019-0001-0001. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act H.R. 1264 and H.R. 1781 and S. 801 - Provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information.